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High-grade serous carcinoma (HGSC) is the most lethal ovarian cancer histotype. The
fallopian tube secretory epithelial cells (FTSECs) are a proposed progenitor cell type.
Genetically altered FTSECs form tumors in mice; however, a spontaneous HGSC model
has not been described. Apart from a subpopulation of genetically predisposed women,
most women develop ovarian cancer spontaneously, which is associated with aging and
lifetime ovulations. A murine oviductal cell line (MOELOW) was developed and continuously
passaged in culture to mimic cellular aging (MOEHIGH). The MOEHIGH cellular model
exhibited a loss of acetylated tubulin consistent with an outgrowth of secretory epithelial
cells in culture. MOEHIGH cells proliferated significantly faster than MOELOW, and the
MOEHIGH cells producedmore 2D foci and 3D soft agar colonies as compared to MOELOW
MOEHIGH were xenografted into athymic female nude mice both in the subcutaneous
and the intraperitoneal compartments. Only the subcutaneous grafts formed tumors
that were negative for cytokeratin, but positive for oviductal markers, such as oviductal
glycoprotein 1 and Pax8. These tumors were considered to be poorly differentiated
carcinoma. The differential molecular profiles between MOEHIGH and MOELOW were
determined using RNA-Seq and confirmed by protein expression to uncover pathways
important in transformation, like the p53 pathway, the FOXM1 pathway, WNT signaling,
and splicing. MOEHIGH had enhanced protein expression of c-myc, Cyclin E, p53, and
FOXM1 with reduced expression of p21. MOEHIGH were also less sensitive to cisplatin
and DMBA, which induce lesions typically repaired by base-excision repair. A model of
spontaneous tumorogenesis was generated starting with normal oviductal cells. Their
transition to cancer involved alterations in pathways associated with high-grade serous
cancer in humans.
Keywords: carcinogenesis, fallopian tube, cancer, ovarian cancer, and model system
Introduction
Epithelial ovarian cancer (EOC) has a disproportionately high-mortality rate in comparison to other
gynecologic malignancies, ranking first overall (1). The American Cancer Society estimates that
14,180 women will succumb to this disease annually and 21,290 will be newly diagnosed in 2015
(2). EOC can be divided into five common histotypes including mucinous, endometrioid, clear cell,
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low-grade serous, and high-grade serous carcinoma (HGSC) (3).
HGSC is the most prominent EOC histotype and accounts for
nearly 75% of all EOC-related mortality. Moreover, the 5-year
survival rate from 2003 to 2009 was 44%, a mere 8% improvement
from the mortality rates observed 30 years earlier (1). The under-
lying molecular events contributing to initiation and progression
are still lacking, leading to patients rarely being diagnosed in
stage I (4). Aspects contributing to this high-mortality rate are the
debatable cellular origin of the disease and the paucity of models
representing spontaneous tumor formation (5).
The source of EOC is currently being investigated with both the
ovarian surface epithelia (OSE) and the fallopian tube secretory
epithelial cell (FTSEC) serving as possible progenitor populations
(6). The ovarian surface was considered the source of EOC for
decades with recent evidence pointing to the fallopian tube or
both. For example, women undergoing prophylactic salpingo-
oophorectomies due to germ-line mutations in either BRCA1 or
BRCA2 provided pathologists with tissue specimens that con-
tained neoplastic lesions in the fimbriae of the fallopian tubes
(7). Fallopian tube lesions occurred in women with HGSC and
with serous tubal epithelial carcinomas (STICs), leading to the
hypothesis that the fallopian tube secretory epithelium is a poten-
tial source ofHGSC (8). Recent evidence specifically demonstrates
that the secretory epithelial cells of the fallopian tube (or oviduct
in mice) are the source of tubal-derived HGSC (9–11).
There are many well-established cellular and animal models
used to study FTSEC or oviductal epithelial cell transformation
by using SV40, which functionally inhibits both the Rb and
p53 tumor-suppressor pathways (12–15). The concern with using
SV40 is that blocking these two important tumor-suppressor path-
ways as well as overexpressing oncoproteins, such as c-Myc or
H-Ras, will induce tumorigenesis in many, if not all cell types and
that mutation and loss of p53 function are not equivalent (16).
Mutation in p53 is the defining event that is common to 96–100%
of HGSC (17). Genetically modified models have been generated
from both the OSE and FTSECs (18, 19) generally targeting the
specific genes associated with human HGSC (18, 19). This tar-
geted approach to tumorigenesis has provided important evidence
that both OSE and oviductal cells (murine equivalent of fallopian
tube) can form tumors, but lacks information regarding themech-
anisms for these changes to occur. Furthermore, in humandisease,
it is unclear whether these commonly mutated genes are normally
involved in disease initiation and/or progression.
The development of spontaneousmodels of HGSCwould assist
in understanding the origins and progression of this disease. For
decades, the OSE was the primary cell type thought to give rise
to HGSC with numerous cellular and transgenic animal models
supporting this theory (20–24). For example, both rat andmurine
OSE cells isolated and passaged in culture have provided evidence
that the OSE can give rise to tumors that exhibit many phenotypic
and genetic similarities to the human disease (25–28). Another
critical model of spontaneous ovarian cancer is the laying hen,
which mainly develops endometrioid EOC, instead of HGSC, and
has a unique oviduct that primarily functions as a shell gland
(29–31). Therefore, this study focused on the development of
a new spontaneous model of ovarian cancer derived from out-
bred CD1 oviducts. Similar to OSE models, continuous passaging
produced transformed cells that demonstrated unique changes
in transcription consistent with the human disease. This model
provides a unique tool for understanding aspects of tumorigenesis
from oviductal cells. This model may also be used to understand
how cells develop resistance to chemotherapy.
Materials and Methods
Animals
Female CD1 mice were purchased fromHarlan (Indianapolis, IN,
USA) and NCr nu/nu athymic (nude) female mice from Taconic
(Hudson, NY, USA). Animals were treated in direct compliance
with the National Institutes of Health (NIH) Guide for the Care
and Use of Laboratory Animals, using protocols approved by the
Animal Care Committee at the University of Illinois at Chicago
(UIC). Mice were housed in a temperature and light controlled
environment (12 h light, 12 h dark) and provided food and water
ad libitum. Nude mice were euthanized when tumors devel-
oped and based on loss of wellness and humane endpoints. All
mice were euthanized by CO2 asphyxiation followed by cervical
dislocation.
Isolation of Murine Oviductal Epithelial Cells
Primary murine oviductal epithelial (MOE) cells (also called
murine tubal epithelial cells orMTEC) were pooled frommultiple
oviducts to establish one cell line from 8-week-old female CD1
mice, as previously described (32). To ensure purity, oviducts
were carefully excised, and using a dissecting scope, removed the
ovaries, bursa, uterus, and fat pads. MOE cells were maintained in
complete medium containing α-MEM modified Eagle’s medium
(CellGro, Manassas, VA, USA) supplemented with ribonucleo-
sides, deoxynucleosides, and -glutamine and supplemented with
10% fetal bovine serum, 2mM -glutamine (Life Technologies,
Grand Island, NY, USA), 2µg/ml epithelial growth factor, 5µg/ml
insulin, 5µg/ml transferrin, 5 ng/ml sodium selenite (Roche; Indi-
anapolis, IN, USA), 1mg/ml gentamycin (CellGro; Manassas, VA,
USA), and 18.2µg/ml β-estradiol (Sigma Aldrich; St Louis, MO,
USA). MOE cells were maintained in a humidified atmosphere
containing 5% CO2 at 37°C.
Once the primary isolated MOE cells became established in
culture, the MOELOW cells (passages 8–25) were continuously
passaged to generate the experimentally aged, MOEHIGH cells
(passages 85–120). The MOE cells were verified to be clean
of Mycoplasma spp. and 12 other rodent pathogens after anal-
ysis using the IMPACT III Profile test (IDEXX BioResearch,
Columbia, MO, USA).
Western Immunoblotting
Murine oviductal epithelial cells were lysed in modified RIPA
buffer and protein concentration was determined, as previously
described (33).Whole cell lysates in RIPA buffer (30µg/well) were
separated, transferred to nitrocellulose membrane (GE Health-
care Life Sciences, Pittsburgh, PA, USA), blocked, and incubated
with primary antibody shaking at 4°C overnight. Membranes
were incubated with HRP-conjugated secondary antibody and
exposed to SuperSignal West Femto substrate (Thermo Scien-
tific, Waltham, MA, USA). All blots were photographed using
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the FluorChem E documentation system (Protein Simple; Santa
Clara, CA, USA). Densitometry is calculated from three blots.
Primary antibodies include the following: phosphorylated-Rb1
(Ser780), c-myc, p53, E-cadherin, and α-tubulin were all obtained
from Cell Signaling Technology, Inc. (Danvers, MA, USA); cyclin
E1, N-cadherin, and OVGP1 were from Abcam (Cambridge,
MA, USA); p21, p16INK4A, and FoxM1 from Santa Cruz Biotech-
nologies (Santa Cruz, CA, USA); and PAX8 from Proteintech
(Chicago, IL, USA).
MOE Cell RNA Preparation and Sequencing
Using Next-Generation RNA-Sequencing
Technology
MOELOW (passages 8, 9, and 10) and MOEHIGH (passages 90,
103, and 113) cells were plated and at 75% confluency, they
were washed with PBS, lysed, and total RNA extracted in Trizol
reagent (Life Technologies), according tomanufacturer’s protocol.
To ensure that there was no residual genomic DNA contamina-
tion, samples were treated with RNase-free DNase I and RNA
was further purified using RNeasy Mini cleanup (Qiagen Inc.,
Valencia, CA, USA). The concentration of the total RNA was
determined using the NanoVue Plus spectrophotometer provided
by the UIC Resource Research Center Core (GE Healthcare Bio-
Sciences, Piscataway, NJ, USA) and RNA purity as determined by
the RNA integrity number (RIN) was verified using TapeStation
2200 (Agilent Technologies, Palo Alto, CA, USA).
Each total RNA sample had ribosomal RNA removed using
TruSeq Stranded Total RNAwith Ribo-Zero (Illumina, SanDiego,
CA, USA). Strand-specific libraries were constructed and quanti-
tated using Qubit, and cDNAs verified by qPCR. The resulting six
libraries were pooled and sequenced using TruSeq SBS sequencing
kit 3 for 101 cycles on a HiSeq2000 (Illumina) and processed with
Casava (version 1.8.2.), according to the manufacturer’s protocol.
RNA-Seq Transcriptome Analysis
The quality of DNA reads (fastq format) was evaluated using
FastQC. The data were analyzed following the previously
described procedure (34). Briefly, the reads were aligned to the
Mus musculus genome (mm10) using TopHat, version 2.0.8b1.
Aligned reads were used to determine the expression of known
mmu10 gene annotations from the University of California-Santa
Cruz website using Cufflinks version 2.1.12. The individual tran-
script files generated by Cufflinks were merged into a single gene
annotation file and used to determine the differential expression
analysis feature in Cuffdiff.
Differential expression was determined to be statistically sig-
nificant by Cuffdiff using a false discovery rate (FDR)-adjusted
p-value, where significance was set to p 0.05 (35). Differential
expression analysis was processed using R-package (cummeR-
bund) and used to compare theMOELOW andMOEHIGH cells. The
cummeRbund results were used to create a dendrogram compar-
ing the differences between all MOELOW and MOEHIGH cell pas-
sages. Furthermore, pathway analysis was performed on transcript
lists from both cell lines using GeneCoDis to identify the KEGG
1http://tophat.cbcb.umd.edu
2http://cufflinks.cbcb.umd.edu/
and Panther pathways that are significantly different between
MOELOW andMOEHIGH cell lines (36–38). RNA-sequencing tech-
nology (RNA-seq) and data analysis were supported by theNorth-
western University Next-Generation Sequencing Core Facility
and Dr. Matthew Schipma.
Quantitative PCR Analysis
Total RNA (1.0µg) was reverse transcribed using the iScript
cDNA synthesis kit (BioRad), according to manufacturer’s
instructions. cDNA was amplified and analyzed using ViiA7
iCycler real-time SYBRPCRdetection system (Life Technologies).
Samples are normalized relative to the internal control Gapdh
and MOEHIGH cells were compared to the MOELOW cells (∆∆Ct
expressions) of Cdkn1a, Foxm1, Trp53, Ovgp1, and Pax8.
Cell Proliferation
Sulforhodamine B (SRB) assays were used to determine prolifer-
ation of MOE cells, as described previously (33). Briefly, MOE
cells (1.0 103/well) were incubated for 0, 12, 24, 48, and 72 h.
Absorbance was measured at 505 nm using a BioTek Synergy 2
microplate reader (BioTek). All assays were repeated in at least
three biological replicates. For experiments using doxorubicin,
cisplatin, paclitaxel, and DMBA, cells were treated with eight
concentrations in four independent experiments and the data
plotted represent the average cell viability for each concentration.
The values of LC50 were determined from the averaged data that
were fit to the curve using Prism.
Clonogenic Assay
MOELOW and MOEHIGH cells were plated (200 cells/60mm-dish)
and incubated for 6 days. After incubation, cells were washed,
fixed with 4% (w/v) paraformaldehyde, and stained with 0.04%
(w/v) crystal violet for 30min at room temperature. Plates were
washedwith deionizedH2O, dry, and photographed using the Flu-
orChem E documentation system (Protein Simple, Santa Clara,
CA, USA). Numbers of foci were analyzed using Image J software
(NIH) from four biological replicates.
Soft Agar Colony Formation Assay
Murine oviductal epithelial (1.5 104) cells were suspended in
0.35% (w:v) agar on top of a 0.5% (w:v) base agar layer (39).
Cells were incubated for 14 days withmedia changed every 3 days.
Final colonies were imaged on a Nikon Eclipse TS100 microscope
and colonies were counted using Image J software from three
biological replicates.
Tumorgenicity in Nude Mice
The procedure of injections was performed, as previously
described (13). Briefly, both s.c. (1.0 106 cells in Matrigel/
animal) and i.p. (1.0 107 cells in PBS/animal) injections were
done into all mice (n= 5 mice/group). Once palpable, tumor
growth was monitored weekly using digital calipers. Animals
were sacrificed at humane endpoints and tumors were excised,
weighed, and either embedded in paraffin for immunohisto-
chemistry (IHC) or flash frozen in liquid nitrogen for protein
and mRNA analysis. Additionally, gross internal anatomy was
inspected for any signs of i.p. disease.
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Immunohistochemistry
Paraffin-embedded tissues sectioning, H&E staining, and IHC
were completed, as described previously (40). Tissue sections were
incubated with the following primary antibodies overnight at
4°C: anti-CK8 (1:200; Developmental Studies Hybridoma Bank,
Iowa City, IA, USA); anti-Pax8 (1:200; Proteintech, Chicago, IL,
USA); anti-Ki67 and anti-OVGP1 (1:100; Abcam, Cambridge,
MA, USA). DAB staining was used to detect protein expression
in tissue sections. Stained sections were analyzed by a pathologist
(Dr. Jian-Jun Wei, Northwestern University). Slides were imaged
on a Nikon Eclipse E600 microscope using the 40 objective.
Immunofluorescence
Murine oviductal epithelial (5.0 104 cells/well) cells were plated
in an eight-well chamber slide and stained for various proteins,
as previously described (41). Briefly, cells were fixed in 4% (w/v)
PFA, permeabilized with 0.2% (v/v) Triton X-100, blocked with
10% (v/v) goat serum, incubated with primary antibody for 1 h
at room temperature. The primary antibodies used were anti-
Pax8 (1:200; Proteintech, Chicago, IL, USA); and anti-OVGP1
(1:200; Abcam, Cambridge, MA, USA). Proteins were visualized
by incubation with AlexaFluor488 (green) secondary antibodies
and slides were mounted using Vectashield Mounting Medium
containing DAPI (Vector Laboratories; Burlingame, CA, USA).
Slides were imaged on a Nikon Eclipse E600 microscope and
captured using Nikon DigitalSight DS-Ri1 camera.
Statistical Methods
Statistical analysis was carried out using GraphPad Prism soft-
ware (GraphPad Software, La Jolla, CA, USA). All values are
expressed as the means of samples SEM. Statistical significance
was determined by unpaired t-test a p< 0.05 was considered to be
statistically significant.
Results
MOEHIGH Demonstrate In Vitro and In Vivo
Evidence of Spontaneous Cellular Transformation
In order to derive an oviductal cell line, CD1mice were utilized as
a source of primary cells because they are an outbred strain that
might provide a model for human disease. Murine cells were used
to compare to existing ovarian surface models, and because they
typically can be immortalized on plastic without the use of viral
oncoproteins. CD1 cells were confirmed to be of epithelial origin,
as previously described (32). The CD1 cells were then continu-
ously cultured to up to 130 passages to generate two cell mod-
els, MOELOW (passages 5–25) and MOEHIGH (passages 85–120).
Both MOELOW and MOEHIGH expressed oviductal glycoprotein
1 (OVGP1) and PAX8 based on RNA (Figure 1A) and protein
expression (Figure 1B; Figure S1 in Supplementary Material) (42,
43). MOEHIGH cells lost acetylated tubulin and expressed Pax8,
consistent with other oviductal models cultured on plastic that
tend to undergo senescence and lose cilia function that produce an
outgrowth of the secretory subtype of epithelium. Recent evidence
suggests that most HGSC originate from the FTSECs (44). The
outgrowth of secretory cells in fallopian tube fimbria is often
described by pathologists as a putative preneoplastic lesion called
a SCOUT (11).
FIGURE 1 |MOEHIGH lose acetylated tubulin upon serial passaging.
(A) OVGP-1 and Pax8 expression levels were similar in qPCR and RNA
sequencing and not significant (n.s.) between MOEHIGH and MOELOW.
(B) Western blotting on MOEHIGH and MOELOW cell lysates probed for
acetylated tubulin, OVGP-1, PAX8, and normalized to α-tubulin.
MOEHIGH cells were tested for in vitro aspects of transfor-
mation. First, the rate of proliferation of MOEHIGH was com-
pared to MOELOW. MOEHIGH cells proliferated significantly more
than MOELOW after 48 and 72 h (Figure 2A). The average dou-
bling time of MOEHIGH cells was 17.3 h as compared to the
MOELOW doubling time of 24.1 h. Next, a clonogenic assay was
employed tomonitor the ability ofMOEHIGH cells to form colonies
as compared to MOELOW. MOEHIGH cells formed significantly
more clonogenic colonies thanMOELOW after 6 days (Figure 2B).
MOEHIGH demonstrated on average 76 3 colonies or about 38%
of the cells plated formed foci as compared to MOELOW, where
only 9.8% formed foci. Finally, the cells were grown in soft agar
to test whether they exhibited anchorage independent growth.
MOEHIGH cells formed a significant number of soft agar colonies
(14 1) after 14 days, while MOELOW did not form colonies and
persisted as single cells in agar (Figure 2C).
In order to confirmwhether the in vitro characteristics of trans-
formation identified in MOEHIGH contributed to tumor forma-
tion, female athymic nude mice (n= 5 MOEHIGH and MOELOW)
were injected subcutaneously with 1 106 cells and intraperi-
toneally with 1 107 cells. All of the mice injected withMOEHIGH
cells developed subcutaneous tumors that grew over time and ulti-
matelymicewere sacrificed for humane endpoints after an average
of 117 9 days (Figure 3A). MOEHIGH cells failed to develop any
tumors when injected into the peritoneal space.MOELOW failed to
develop tumors in either the s.c. or i.p. sites. Subcutaneous tumors
derived fromMOEHIGH cells were evaluated by a pathologist based
on morphological features from H&E staining as well as using a
variety of immunohistochemical stains. Tumors were solid with
spindle-like structures and were highly cellular with moderate
nuclear atypia and abundant mitosis (Figure 3B). The morphol-
ogy was sarcoma like with infiltration of the tumor identified
in the skeletal muscle. The tumors were highly mesenchymal
exhibiting little or no cytokeratin 8 (Figure 3C) positivity orWT1
staining (not shown). OVGP1 and Pax8 are markers of Müllerian
origin, and PAX8 is used to classify tumors as the serous histotype.
Tumors were OVGP1 positive (Figure 3D), demonstrated some
Pax8 positivity, but it was both nuclear and cytoplasmic as well
as sporadic (Figure 3E). A high percentage of tumor cells stained
with Ki67 indicating increased proliferation (Figure 3F). Tumors
did not express stabilized p53 (Figure 3G). Overall, the tumors
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FIGURE 2 |MOEHIGH cells demonstrate in vitro aspects of
transformation, such as enhanced proliferation, foci formation, and
soft agar colony growth, as compared to MOELOW. (A) Proliferation of
MOEHIGH and MOELOW cells was analyzed using SRB assay and data
calculated as the fold change from day 0. (B) MOEHIGH and MOELOW cells
were tested for 2D colony formation after 6 days using a clonogenic assay.
(C) MOEHIGH and MOELOW cells were analyzed for soft agar colony formation
after 14 days. *p-value >0.01.
were considered poorly differentiated spindle cell neoplasia of
oviductal origin.
Transcriptome of MOEHIGH Reveals Changes
Responsible for Transformation
In order to reveal some of the pathways that might contribute
to tumor formation of MOEHIGH cells, RNA sequencing was
performed on three different passages of MOELOW (8, 9, 10) as
compared to MOEHIGH (90, 103, 113). Samples were barcoded
and sequenced using Illumina HiSeq2500 sequencing. Samples
FIGURE 3 |MOEHIGH cells undergo spontaneous transformation and
form tumors. (A) Athymic female nude mice were injected subcutaneously
and intraperitoneally with MOEHIGH and MOELOW cells. MOEHIGH formed
subcutaneous tumors but not intraperitoneal explants. MOELOW cells failed to
form any tumors. Tumor volume was measured with calipers. Hematoxylin
and Eosin staining (B) and immunohistochemistry (C–G) performed on s.c.
MOEHIGH tumors. Tumors were malignant, undifferentiated, and mesenchymal
and were negative for CK8 (C). Tumors were of oviductal origin staining
positive for OVGP1 (D) and Pax8 (E). Tumors were highly proliferative based
on positive Ki67 (F) and did not demonstrate stabilized p53 (G). Scale
bars = 100µm.
clustered based on passage number using a dendrogram analysis
(Figure S2 in Supplementary Material). The top 20 most signifi-
cantly up- and down-regulated transcripts are shown in Table 1.
Pathway analysis revealed that the most highly upregulated bio-
logical processes involved the splicesome, RNA transport, the cell
cycle, and DNA replication (Figure 4). Biological processes that
were repressed included processing in the endoplasmic reticulum,
focal adhesion, pathways in cancer, and the lysosome.
MOEHIGH Cells Harbor Splice Variant of p53 with
Differential Action on Target Genes
The cancer genome atlas helped to define critical pathways altered
in high-grade serous tumors (17). In order to compare MOEHIGH
to human tumor samples, pathways implicated in human disease
were interrogated. RNA sequencing revealed that p53 inMOELOW
and MOEHIGH cells was not mutated; however, MOEHIGH cells
had a significant upregulation of a splice variant of p53 that has
the last 26 amino acids eliminated and has 16 unique residues
replaced (SLQPRAFQALIKEESPNC). This splice variant due to
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TABLE 1 | Table showing the list of genes that were significantly regulated in MOEHIGH cells from RNA sequencing analysis.
Gene name RefSeq ID RPKM 1 RPKM 2 Log2 fold change FDR-adjusted p-value Fold change
1 Adam19 NM_009616 16:81 0:01  10:73 0:033 1698:92
2 Fbln5 NM_011812 16:12 0:01  10:65 0:0397 1612:29
3 Gpc4 NM_008150 73:1 0:05  10:47 0:0002 1421:01
4 Aldh1a2 NM_009022 99:25 0:07  10:47 0:001 1413:93
5 Meg3, Mir1906-1, Mir770 NR_030427 35:16 0:03  10:2 0:0005 1176:35
6 Myl9 NM_172118 692:44 0:59  10:2 0:0002 1175:7
7 Igfbp2 NM_008342 411:81 0:39  10:06 0:0002 1066:45
8 Bgn NM_007542 194:46 0:2  9:91 0:0002 961:53
9 Dkk3 NM_015814 145:8 0:16  9:83 0:0002 909:81
10 Rcn3 NM_026555 201:24 0:24  9:73 0:0002 851:81
11 Ar NM_013476 6:72 0:01  9:7 0:0172 833:48
12 Acta2 NM_007392 4445:02 5:73  9:6 0:0002 775:58
13 Gpx3 NM_008161 101:12 0:14  9:54 0:0002 745:5
14 Lox NM_010728 92:18 0:13  9:46 0:0002 706:53
15 Col1a2 NM_007743 133:43 0:19  9:46 0:0002 702:45
16 Luzp2 NM_178705 11:05 0:02  9:43 0:0264 689:72
17 Tagln NM_011526 4014:57 6:11  9:36 0:0002 656:56
18 Thbd NM_009378 12:43 0:02  9:36 0:0452 656:18
19 Itih2 NM_010582 43:31 0:07  9:36 0:0002 655:09
20 Rian NR_028261 34:51 0:06  9:29 0:0002 626:01
21 Wnt7b NM_009528 0:08 36:78 8:77 0:00017 436:14
22 Gsta1 NM_008181 0:08 31:37 8:66 0:00648 403:5
23 Myo16 NM_001081397 0:01 2:83 8:42 0:01787 342:22
24 Ccnb1ip1 CUFF.5283.1 0:2 44:25 7:81 0:00017 224:45
25 Slco2a1 NM_033314 0:13 29:46 7:77 0:00017 218:98
26 Adh7 NM_009626 0:47 102:2 7:77 0:00017 218:97
27 Cdh16 NM_001252627 0:35 50:13 7:17 0:00017 144:34
28 Mrc1 NM_008625 0:1 12:8 6:94 0:00017 122:91
29 Aqp5 NM_009701 0:51 60:08 6:88 0:00017 117:65
30 Nup210 NM_018815 0:05 4:97 6:78 0:00017 109:99
31 Upk1b NM_178924 0:65 69 6:73 0:00017 106:28
32 Arhgef26 NM_001081295 0:02 2:1 6:64 0:00105 99:51
33 Itgb2 NM_008404 0:43 42:78 6:63 0:00017 99:26
34 Crb2 NM_001163566 0:16 15:21 6:56 0:00017 94:38
35 Ppl NM_008909 0:53 45:97 6:45 0:00017 87:52
36 Prl2c2 NM_031191 1:96 168:62 6:43 0:00017 86:23
37 Ano1 NM_001242349 0:47 39:5 6:39 0:00017 84
38 Fmnl1 NM_019679 0:14 11:08 6:3 0:00017 78:76
39 Cxcl5 NM_009141 0:09 6:83 6:29 0:00223 78:09
40 Mgst2 NM_174995 0:38 28:35 6:22 0:00062 74:59
Genes from 1 to 20 were downregulated and genes from 21 to 40 were upregulated.
the elimination of 26 amino acids has 6 phosphorylation site
removed that serve as regulatory domains important for MDM2-
mediated ubiquitination (45). As a result, western blots revealed
a more intense band for p53. Several p53 target genes of p53
were investigated from the RNA-seq data to help characterize
the transcriptional action of the p53 alternative splice variant
(Table 2). FoxM1 is typically repressed by wild-type (WT) p53
and amplified when p53 has a DNA-binding mutation (46, 47).
Cdkn1a (or p21) is also positively regulated by p53 and mutation
or loss of p53 results in a lack of induction (33, 48). Thbs1 is
enhanced in the presence of WT p53 and p53 null cells compared
to those harboring amissensemutation (49). InMOEHIGH, FoxM1
RNA was enhanced by 1.59-fold in the RNA-seq data, p21 was
repressed by 1.98-fold, and Thbs1 was repressed 17-fold. There-
fore, RNA expression for FoxM1, p21, and Thbs1 indicated that
these genes were regulated by the p53AS in a similar manner to
missense or gain-of-function mutations in p53. WT p53 induces
MDM2 expression, while mutation typically results in poor or
repressed activation of the MDM2 promoter, but no significant
change was found at the RNA level of MDM2 (50). IGFBP3 has
a possible 11 p53-responsive elements in the promoter and also
in an intronic sequence that is frequently methylated, which can
block p53 induction of this target (51). TheMOEHIGH that express
a splice variant of p53 also expressed a 4.86 induction of the RNA
(IGFBP3) transcript compared to MOELOW. These results suggest
that the p53AS has mixed functions acting more like WT p53
on some transcriptional targets, such as IGFBP3, and more like
missense p53 on FoxM1, p21, and Thbs1 gene regulation.
Key Pathways Altered in Human HGSC are also
Modified in MOEHIGH
The TCGA highlighted several players that were altered in a
large percentage of human tissue samples. These targets were
investigated using western blot in MOEHIGH compared to
MOELOW (Figure 5A). While the p53 DNA-binding domain was
not mutated, the protein expression was higher in MOEHIGH.
WT p53 induces p21 expression, yet p21 was repressed at the
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FIGURE 4 | RNA sequencing reveals biological processes altered in MOEHIGH cells. Gene ontology analysis of the pathways that were altered in MOEHIGH
cells compared to MOELOW. Green bars represent pathways that were upregulated and red bars indicate the downregulated pathways.
TABLE 2 | p53 splice variant alters the mRNA expression of p53 target
genes.
Transcripts MOELOW MOEHIGH Fold
change
FDR-adjusted
p-value
Trp53 (p53) splice variant 79:62 111:81 1:40 0.0006
Foxm1 22:43 35:61 1:59 0.0002
Cdkn1a (p21) 158:98 80:15  1:98 0.0002
Thbs1 281:28 16:52  17:03 0.0002
Mdm2 64:97 61:03 1:28 0.5745
Igfbp3 16:65 80:93 4:86 0.0002
RNA sequencing revealed expression of an alternatively spliced p53 transcript vari-
ant MOEHIGH cells. Foxm1 was upregulated, Cdkn1a was repressed, and Thbs1 was
repressed similar to regulation of these promoters by p53 containing a DNA-binding
mutation. MDM2 regulation was unchanged, while Igfbp3 was upregulated similar to
wild-type p53 action.
protein level, similar to human tumors that have a reduction
due to mutation and/or downregulation in 7% of tumors. Cyclin
E1 is amplified in about 20% of human HGSCs and the protein
was elevated in the MOEHIGH cells. Differential regulation of
the Rb pathway was reported in TCGA data, and the MOEHIGH
showed an increase in phospho-Rb protein, a loss of p16INK4A
protein, and amplified CCND1 transcript (RNA sequencing) (17).
Lastly, c-myc and FoxM1 proteins were elevated in MOEHIGH as
compared to MOELOW.
The FOXM1 pathway was amplified in roughly 90% of high-
grade serous tumors according to the TCGA analysis (17). Since
FoxM1 was amplified at an RNA and protein level, the pathways
noted by the TCGA that were altered in human tissue samples
were monitored in the RNA-seq results. The TCGA reported
on the following transcripts that are regulated in the FOXM1
pathway, all of which (or their mouse homolog) were amplified
in the TCGA data set and in the MOEHIGH cell model: CHEK2,
ATR, BRCA1, BRCA2, RAD51, CDC25B, BIRC5, AURKB, PLK1,
and CCNB1 (Figure 5B).
MOEHIGH are Resistant to DNA Bulky Strand
Adducting Pathways
One of the hallmarks of HGSC is the development of resis-
tance to chemotherapy, and typically resistance occurs to carbo-
platin, although patients can also become resistant to paclitaxel
(52). In order to determine if MOEHIGH exhibited any differen-
tial response to chemotherapy, concentration-dependent growth
curves were generated in response to the commonly used front-
line therapies for ovarian cancer, cisplatin, and paclitaxel. The
MOEHIGH cells were less sensitive to cisplatin demonstrating
an LC50 of 541 nM, which was almost double that of MOELOW
(245 nM) (Figure 6B). Similarly, DMBA, which forms DNA
adducts repaired by nucleotide excision repair, was able to induce
cell death in MOELOW at an LC50 of 297 nM, while MOEHIGH
required 10.3µM to induce death (Figure 6A). Interestingly, the
cells displayed no significant differences in response to doxoru-
bicin and paclitaxel (Figure S3 in SupplementaryMaterial). There-
fore, the MOEHIGH transformed cellular model may also provide
some insights into changes that allow oviductal-derived tumor
cells to develop resistance to cisplatin and other bulky adducting
compounds, like DMBA.
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FIGURE 5 |MOEHIGH cells have several pathways regulated similarly to
human high-grade serous tumors. (A) Western blotting analysis on
MOEHIGH and MOELOW cells probed for targets that have differential regulation
in human tissue samples based on the TCGA database. p53 protein levels
were elevated in MOEHIGH cells due to overexpression of p53 splice variant.
Cyclin E, pRB (S780), c-Myc, and FoxM1 expression levels were increased
and p21 and p16INK4A expression levels were decreased in MOEHIGH
compared to MOELOW. Numbers under blots for Cyclin E, c-Myc, and FoxM1
represent fold change in densitometry between MOEHIGH and MOELOW
normalized to tubulin. Number under pRB (S780) blot represent fold change
in densitometry between MOEHIGH and MOELOW normalized to total RB.
(B) FoxM1 pathway modified in MOEHIGH similar to human high-grade serous
tumors. Fold increase in RNA expression from MOEHIGH compared to
MOELOW from RNA-seq is shown in green.
Discussion
While several transgenic mouse models and engineered cell mod-
els have demonstrated that oviductal epithelium can form HGSC,
a spontaneousmodel of tumor formation from the oviduct has not
yet been reported. Spontaneous models of OSE after continuous
passage have been used for many studies including studies that
help to understand the progression of cancer and the properties of
the cells, such as aneuploidy, transcriptional alterations, enhanced
stem-cell like properties, response to chemotherapy, and as a
syngeneic model (26, 28). Continuous passaging of primary, non-
tumor forming CD1 oviductal cells revealed that they became
more secretory dominated in culture, proliferated more rapidly,
formed 2D foci and soft agar colonies. RNA profiling revealed
several pathways modified in the cellular model that were also
altered in HGSC, such as FoxM1. Similar to models derived from
OSE, the tumors were mostly undifferentiated, but they expressed
oviductal markers. The MOEHIGH cells demonstrated a resistance
to cisplatin and DMBA, but not to doxorubicin, H2O2, and pacli-
taxel. Overall, these studies provide a unique cellular model that
can be used to monitor the changes that accumulate over time
to produce a spontaneous tumor from oviductal cells exposed to
continuous passaging.
MOEHIGH represent the first spontaneous cellular model of
cancer derived from an oviductal cell line. This model serves as
a complimentary model system to several similar ones derived
from the OSE of rats and mice (25, 28, 53–55). While all of
these models are tumorigenic, almost all of them produced undif-
ferentiated tumors, similar to the MOEHIGH in this study. Only
recently, a spontaneous OSE model was generated that exhibited
not only phenotypic aspects of HGSC but also molecular ones
(28). MOEHIGH while lacking expression for several common
immunohistochemical markers for HGSC, such as cytokeratin
8, did express Pax8 and oviductal glycoprotein confirming their
oviductal origin. MOEHIGH is also the first spontaneous model
from an outbred strain, as previous OSE models have been gen-
erated from C57Bl/6 or FVB strains. MOEHIGH could potentially
be grafted into immune competent hosts, but difficulty has been
reported in the literature for allografting into outbred hosts, such
as CD1 mice (56). The enhanced genetic diversity on an outbred
strainmay provide a better tool to uncoveringmechanisms behind
spontaneous tumor formation.
The most common mutation in human HGSC is in p53, typ-
ically found in the DNA-binding domain. While MOEHIGH cells
did not display a standard DNA-binding mutation, the protein
was alternatively spliced such that it lacks negative c-terminal
regulatory domains. Interestingly, this splice variant could func-
tion similarly to truncation mutations found in the c-terminus of
the human gene, which was demonstrated to lack growth arrest
and apoptotic functions (57). Ceramide, an inhibitor of SRSF1
splicing activity, was recently shown to restore WT p53 function
and could be a potential way to re-activate WT p53 in “deletion”
mutated cells (58). Given that the model is of murine origin, and
rodents have been shown to have unique splicing of p53, certain
aspects of this model may be species specific (59). In addition, the
MOEHIGH cellular model did not demonstrate any mutations in
BRCA1 or 2, but consistent with human disease, had amplification
of cyclin E1. Human tumors exhibit a mutual exclusivity between
BRCA mutations and cyclin E amplifications (60). MOEHIGH did
recapitulate some of the pathway modifications typically seen in
HGSC, such as amplification of FoxM1 and its targets, amplifica-
tion of the c-myc protein, cyclin E, reduced Rb function, and a
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FIGURE 6 |MOEHIGH cells display chemoresistance. MOEHIGH and MOELOW cells were treated with DMBA (A) and cisplatin (B). MeanSEM *p-value 0.05
and not significant (n.s.).
loss of p16INK4a. This is important because most of the original
evidence supporting the origin of HGSC came from women with
mutations in BRCA1/2 or from genetically engineered mouse
models with BRCA1/2 floxed alleles deleted in fallopian (oviduc-
tal) cells. The MOEHIGH model demonstrates that in the absence
of BRCA mutation and/or loss, those oviductal cells can become
tumorigenic, and recapitulatemany of the dysfunctional pathways
associated with HGSC.
RNA sequencing of MOEHIGH cells revealed the important
biological processes or pathways that were modified included
splicing, WNT signaling, and DNA synthesis. While DNA syn-
thesis is not surprising given the high rate of proliferation,
pathway modification of splicing, and WNT are consistent with
findings from HGSC and represent possible therapeutic tar-
gets (61–63). WNT signaling is essential in the developmen-
tal origins of the oviductal cells, and the dual role of many
developmental factors is linked with tumor formation. HGSC
has a variety of WNT factors dysregulated including Wnt5a,
Wnt11, Wnt7a, and Sox7 (64–66), and inhibition of certain
WNT targets, such as GSK3β, has shown efficacy in preclinical
xenograft models (67). While several WNT pathway members
were downregulated, such as Fzd2, 4, 5, and 8, soluble ligands,
such as WNT4, and target genes, such as cyclin D1 and Myc,
were amplified. Interestingly, a recently defined spontaneous
ovarian tumor model from the OSE also displayed changes in
Wnt signaling, suggesting that regardless of cellular origin, cer-
tain pathways may provide ideal new drug targets for HGSC
cancers (28).
The MOEHIGH cellular model did not form peritoneal disease,
and was only able to form tumors in the subcutaneous space,
which was reflected in a downregulation of “pathways in cancer”
in the KEGG results where most of the genes were metastatic
or tumor suppressors. Perhaps, the cellular model does not form
widely disseminated tumors because key pathways in ovarian
cancer were not disrupted, such as BRCA or PTEN. Another
possible explanation is that there are key signaling molecules
that block peritoneal dissemination that are still present in the
cells, and perhaps uncovering these will provide new targets to
exploit for reducing peritoneal spread. One such pathway that
was still present in the cells was Pax2 (data not shown). Pax2 is
typically lost in early lesions of HGSC, and studies have demon-
strated that re-expression of Pax2 in HGSC can induce cellular
death (68). Several other in vitro-derived models of fallopian
or oviductal cancer have primarily been xenografted into SCID
mice, and perhaps the difference in background strain influences
the spread of the disease. Lastly, xenografting directly into the
ovarian bursa may increase the chance of developing an early
stage tumor that may be required before subsequent peritoneal
spread.
In summary, a spontaneous model of oviductal cancer was
derived by continuously passaging using an outbred CD1 murine
cell line that developed features of HGSC, such as amplification of
FOXM1 and c-myc, resistance to cisplatin, and loss of Cdkn2a.
The model produced tumors only in the s.c. compartment and
may represent early disease or a model that lacks key regula-
tors of peritoneal spread. Further investigation is warranted to
understand the role of splicing and WNT signaling in this model
system. This model offers the opportunity to uncover a step-
wise progression of tumor formation from an oviductal origin to
be compared to human disease, derived from possibly both the
ovarian surface and the oviduct.
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